Journal of Modern Oncology

Theoretical and practical publication

Journal of Modern Oncology
(Sovremennaya onkologiya) 

The Journal of Modern Oncology (Sovremennaya Onkologiya) is a peer-reviewed, open-access periodical that since 1999 serves the interests of oncologists.

Peer-reviewed theoretical and practical Journal of Modern Oncology is published since 1999 in 5000 copies, volume of about 80 pages of format А4. The journal has been included into the List of periodical scientific and technical publications issued in the Russian Federation where basic scientific results of doctoral thesis should be published. The territory of dissemination of the journal: Russian Federation, countries of Commonwealth of Independent States (CIS) and other foreign countries. 

This periodical publishes papers of scientists and practitioners-oncologists and clinical pharmacologist not only from Russia as well as from the near and far abroad. The journal publishes articles on modern methods of diagnostics and treatment. The journal is issued regularly with periodicity 4 issues a year. At the present time the journal has acquired wide recognition and popularity among specialists.

The journal is disseminated among doctors and researchers working on oncology, modern methods of diagnostics and treatment, officials and specialists of agencies of healthcare of regions of Russian Federation and other foreign countries, Research Institutes; across medical institutions and research centers; into central libraries; by subscription; into all medical libraries.

The "Journal of Modern Oncology" is an open access, peer-reviewed online journal dedicated to providing the very latest information both in clinical and translational research fields related to a wide range of topics in oncology. 

The journal publishes editorial conference updates, original research, reviews, clinical case reports, commentaries, clinical and laboratory observations by Russian and international authors, pertinent to readers in CIS countries and around the world.

The Journal emphasizes vigorous peer-reviewing and accepts papers in Russian and English with most rapid turnaround time possible from submission to publication. Abstracts for all papers are available in both languages.

Special area focus/ journal sections:

  •  Diagnosis of cancer
  •  Tumors of the respiratory system
  •  Ovarian and cervical tumors
  •  Tumors of the digestive tract
  •  Radiation therapy, chemotherapy, targeted therapy of tumors
  •  Quality of life of patients
ISSN 1815-1434 (print)

ISSN 1815-1442 (online)


No announcements have been published.
More Announcements...

Current Issue

Vol 22, No 2 (2020)

Hodgkin's lymphoma
Demina E.A., Tumyan G.S., Moiseeva T.N., Mikhailova N.B., Myakova N.V., Rumyantsev A.G., Maschan A.A., Kaplanov K.D., Shmakov R.G., Falaleeva N.A., Ptushkin V.V., Osmanov E.A., Poddubnaya I.V., Baikov V.V., Kovrigina A.M., Konovalov D.M., Trofimova O.P., Sotnikov V.M., Ilin N.V., Vinogradova Y.N., Nechesnyuk A.V., Parkhomenko R.A., Stefanov D.N., Nevolsky A.A., Ivanov S.A., Khaylova Z.V.

Clinical recommendations.

Journal of Modern Oncology. 2020;22(2):6-33
Follicular lymphoma
Babicheva L.G., Tumyan G.S., Osmanov E.A., Falaleeva N.A., Kravchenko S.K., Stefanov D.N., Poddubnaya I.V., Myakova N.V., Rumyantsev A.G., Maschan A.A., Ptushkin V.V., Baikov V.V., Kovrigina A.M., Krivolapov I.A., Konovalov D.M., Nevolsky A.A., Ivanov S.A., Khaylova Z.V., Gevorkian T.G.

Clinical recommendations.

Journal of Modern Oncology. 2020;22(2):34-51
Conference Proceedings
Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic
Poddubnaya I.V., Baryakh E.A., Vorobyev V.I., Demina E.A., Zhukov N.V., Kaplanov K.D., Konstantinova T.S., Motorin D.V., Ptushkin V.V., Sarzhevsky V.O., Tumyan G.S.

Relevance. COVID-19 pandemic currently has a significant negative impact on the treatment of patients with oncological pathology, including patients with classic Hodgkin lymphoma. Generalized data on publications on the impact of concomitant pathology on the severity of infection show a significant increase in the risk of death from infection in male patients, aged >60 years, with the presence of ≥3 concomitant diseases, among which particularly negative role is played by diseases of the cardiovascular system, diabetes, oncology, chronic lung disease, immunodeficiency conditions. Particularly dangerous is the development of COVID-19 infection in an interval of less than 14 days from the course of antitumor therapy. At the same time, patients with Hodgkin lymphoma require immediate treatment, often associated with toxic, immunosuppressive therapy, frequent visits to the clinic, hospitalizations. International communities have not yet developed clear guidelines for the management of patients with Hodgkin’s lymphoma. Taking into account the understanding that the circulation of coronoviral infection will continue in the population, the Advisory board on the Problems of Hodgkin Lymphoma Therapy in the COVID-19 Pandemic is highly relevant.

Aim. To change and adapt current treatment approaches in the current epidemiological environment.

Results. The main directions of the impact of the COVID-19 pandemic on the treatment of patients with cancer pathology, including patients with classical Hodgkin lymphoma, were determined, key problems in the treatment of LC during the COVID-19 pandemic were identified, and measures aimed at reducing the risk for patients were developed. Existing approaches to first-line, relapse/refracturing cHL therapy, including salvage therapy, and auto/allo SCT during the COVID-19 pandemic, have been adapted.

Journal of Modern Oncology. 2020;22(2):52-55
New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas
Poddubnaya I.V., Ptushkin V.V., Belousova I.E., Gorenkova L.G., Kaplanov K.D., Karamova A.E., Kovrigina A.M., Kolomeitsev O.A., Konstantinova T.S., Kokhan M.M., Pospelova T.I.

Relevance. Cutaneous T-cell lymphomas (CTCL) are not common diseases which are associated with a decrease in quality of life. Currently available systemic therapy rarely provides a stable and long-termed response. In Russia, current CTCL therapy is a big issue due to the limited access to modern targeted therapy, an absence of a National CTCL registry, and the difficulties in morphological diagnosis of these rare diseases. Since June 17, 2019, a new indication of brentuximab vedotin as a new treatment option for patients with CD30+ CTCL after at least one line of previous systemic therapy was registered. Brentuximab vedotin is a conjugate of a CD30 directed monoclonal antibody and an antitumor agent. Brentuximab vedotin is a CD30-directed monoclonal antibody conjugated to an antitumor agent.

Aim. To identify the unresolved issues of current clinical practice and to adapt available approaches to the treatment and diagnosis of CD30 + CTCL given new therapeutic opportunities.

Results. The available approaches to the systemic CTCL therapy in Russia routine clinical practice have been discussed, the unresolved issues of therapy and diagnosis have been identified, the routing of patients with CD30 + CTCL in Russia has been discussed, the importance of CD30 testing has been established, the profiles of patients with CTCL for treatment with brentuximab vedotin have been determined.

Journal of Modern Oncology. 2020;22(2):79-81
Новые возможности системной терапии CD30+ первичных кожных Т-клеточных лимфом. Резолюция

Актуальность. Т-клеточные лимфомы кожи (ТКЛК) – это редкие, ассоциирующиеся со снижением качества жизни заболевания. Доступная на сегодняшний день системная терапия редко обеспечивает достижение стойкого и длительного ответа. В России в настоящий момент терапия ТКЛК представляет собой существенную проблему в связи с ограниченным доступом к современной таргетной терапии, отсутствием Национального регистра ТКЛК, сложностями морфологической диагностики данных редких заболеваний. С 17 июня 2019 г. зарегистрировано новое показание брентуксимаба ведотина – в качестве новой опции лечения пациентов с CD30+ ТКЛК после минимум одной линии предшествующей системной терапии. Брентуксимаб ведотин представляет собой конъюгат CD30-направленного моноклонального антитела и противоопухолевого агента.

Цель. Выявить нерешенные проблемы текущей клинической практики и адаптировать существующие подходы к лечению и диагностике CD30+ ТКЛК с учетом новых терапевтических возможностей.

Результаты. Обсуждены существующие подходы к системной терапии ТКЛК в рутинной клинической практике России, определены нерешенные проблемы терапии и диагностики, обсуждена маршрутизация пациентов с CD30+ ТКЛК в России, определена важность CD30-тестирования, определены профили пациентов с ТКЛК на терапию брентуксимабом ведотином.

Journal of Modern Oncology. 2020;22(2):79-81
Особенности ведения онкологических пациентов во время пандемии коронавирусной инфекции COVID-19
., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., .

Учебный модуль разработан коллективом кафедры под руководством зав. кафедрой академика РАН, профессора И.В. Поддубной и ректора ФГБОУ ДПО РМАНПО Минздрава России, чл.-кор. РАН, профессора Д.А. Сычева.

Journal of Modern Oncology. 2020;22(2):56-73
Original Article
Maintenance oncohematological patients and new coronavirus infection: experience of the City Clinical Hospital №52
Baryakh E.A., Kochneva O.L., Misyurina E.N., Zhelnova E.I., Yatskov K.V., Zagrebneva A.I., Zyangirov R.R., Samsonova I.V., Poteshkina N.G., Lysenko M.A., Poddubnaya I.V.

Justification. Oncological diseases, along with diabetes, hypertension, cardiovascular and chronic obstructive pulmonary diseases, are associated with severe course and worst prognosis of the new coronavirus infection – COVID-19. Due to the limited number of the international studies and the lack of the domestic publications on the analysis of the course of COVID-19 in patients with oncohematological pathology and the patient management tactics, this work seems extremely topical.

Materials and methods. 24.04.2020–31.05.2020, 110 patients with oncohematological pathology associated with new coronavirus infection were observed on the basis of the hematology service of City Clinical Hospital №52: 59 women and 51 men, mean age 58 (18–90) years.

Results. Currently, 24 (22%) patients among 110 are continuing treatment. The outcome of the disease is observed in 86 (78%) patients: 50 (58%) patients were discharged from hospital with complete or partial resolution of pneumonia, 36 (42%) of the 86 patients died. The groups did not differ in gender. The median age was higher in the group of deceased patients (66 vs. 54 years in patients who had a favorable outcome after COVID-19). The somatic status ECOG 3–4 was an independent predictive factor determining the adverse outcome of the disease. The third part of the patients from the group with a fatal cases due to a severe condition in the debut of the disease immediately were hospitalized in the intensive care unit (ICU), 2 (6%) of them had died within the first day. Disposition, according to the nosology showed a significant predominance among patients with an adverse outcome associated with acute leukemia (18% vs 39%). Patients with resistant course of hemoblastosis accounted for 50% of deceased patients. Severe form of the course of COVID-19 infection was twice as frequently (46% vs 84%) among patients with an adverse outcome of the disease, that was associated with both the initial more severe group of patients (33% were hospitalized in the ICU), and less curability of pneumonia against the background of the adverse prognostic factors: the older age group, the predominance of patients with acute leukemia and resistant course of oncohematological diseases. Specific anticancer therapy and COVID-19 therapy were comparable in both groups.

Conclusions. Identification of new coronavirus infection against a backdrop of oncohematological disease is associated with a severe course of COVID-19 and high death rate – 42%. According to the preliminary obtained results, the adverse prognostic factors of COVID-19 in patients with oncohematological diseases include: elderly age, the poor somatic status (ECOG 3–4), relapse or progression of hemoblastosis and nosological affiliation to acute leukemia.

Journal of Modern Oncology. 2020;22(2):74-78

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies